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V. Theodorou5, A. Prekates7, E. Antypa8, V. Koulouras9, N. Kapravelos10, C. Gogos11, E. Antoniadou8, K. Mandragos3 and
A. Armaganidis4, on behalf of the Hellenic Sepsis Study Group
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Thessaloniki and 11) Department of Internal Medicine, University of Patras, Medical School, GreeceAbstractThe emergence of infections by multidrug-resistant (MDR) Gram-negative bacteria, which is accompanied by considerable mortality due to
inappropriate therapy, led to the investigation of whether adjunctive treatment with one polyclonal IgM-enriched immunoglobulin
preparation (IgGAM) would improve outcomes. One hundred patients in Greece with microbiologically conﬁrmed severe infections by
MDR Gram-negative bacteria acquired after admission to the Intensive Care Unit and treated with IgGAM were retrospectively analysed
from a large prospective multicentre cohort. A similar number of patient comparators well-matched for stage of sepsis, source of
infection, appropriateness of antimicrobials and co-morbidities coming from the same cohort were selected. All-cause 28-day mortality
was the primary end point; mortality by extensively drug-resistant (XDR) pathogens and time to breakthrough bacteraemia were the
secondary end points. Fifty-eight of the comparators and 39 of the IgGAM-treated cases died by day 28 (p 0.011). The OR for death
under IgGAM treatment was 0.46 (95% CI 0.26–0.85). Stepwise regression analysis revealed that IgGAM was associated with favourable
outcome whereas acute coagulopathy, cardiovascular failure, chronic obstructive pulmonary disease and chronic renal disease were
associated with unfavourable outcome. Thirty-nine of 62 comparators (62.9%) were infected by XDR Gram-negative bacteria and died by
day 28 compared with 25 of 65 cases treated with IgGAM (38.5%) (p 0.008). Median times to breakthrough bacteraemia were 4 days
and 10 days, respectively (p <0.0001). Results favour the use of IgGAM as an adjunct to antimicrobial treatment for the management of
septic shock caused by MDR Gram-negative bacteria. A prospective randomized trial is warranted.
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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This is an open access artiIntroductionIn many parts of the world, species of Gram-negative bacteria
that are multidrug-resistant (MDR) to commonly prescribed
antimicrobials predominate as pathogens of severe sepsis [1,2].
These MDR species emerge after exposure of patients toClin Microbiol Infect 2016; 22: 499–506
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species of Acinetobacter baumannii, Klebsiella pneumoniae and
Pseudomonas aeruginosa are the commonest pathogens of se-
vere infections acquired after admission to Intensive Care Units
(ICU); resistance to carbapenems exceeds 65% [3].
High resistance rates generate major problems of inappro-
priate antimicrobial therapy with poor outcomes, highlighting
an unmet need for treatment. These severe infections are also
characterized by impairment of the innate immune defence for
effective phagocytosis of bacteria [4]. Enhancement of the
opsonization by IgM may be a promising strategy for the
containment of MDR Gram-negative bacteria. IgM forms pen-
tamers that opsonize invading pathogens and facilitate phago-
cytosis. This was shown by the promising results of one
prospective open-label single-arm study in a limited number of
patients with ventilator-associated pneumonia (VAP) caused by
isolates of P. aeruginosa serotype O11 [5]. As a next step, it is
expected that the use of existing immunoglobulin preparations
enriched with IgM will be more effective than the use of IgM
antibodies directed against speciﬁc sites due to the polyvalence
of polyclonal preparations. The only available polyclonal prep-
aration enriched with IgM immunoglobulins is Pentaglobin®
(Biotest AG, Dreieich, Germany), which contains 76% IgG, 12%
IgA and 12% IgM (IgGAM). IgGAM induces in vitro killing of
MDR clinical isolates of K. pneumoniae through enhancement of
phagocytosis [6].
The Hellenic Sepsis Study Group (HSSG, www.sepsis.gr) is
collecting a prospective cohort of clinical data from patients
with severe infections from Greek hospitals. We conducted a
retrospective analysis of the outcome of severe infections due
to MDR Gram-negative pathogens developing after ICU
admission for which treatment with IgGAM was administered;
results were compared with those of untreated matched
comparators from the same departments at the same time
period.Patients and methodsStudy design
A prospective registry protocol has been running since July
2006 at 63 study sites of the HSSG in Greece after approval by
the Ethics Committees of the participating hospitals. Approval
was granted for the analysis of the use of antimicrobial and
adjunctive therapies administered to enrolled patients at the
discretion of the attending physicians. Patients are enrolled af-
ter written informed consent to use their clinical data for this
analysis; consent is provided by the patients themselves or by
ﬁrst-degree relatives for patients unable to consent. Sepsis
stages and infections are deﬁned by internationally accepted© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licedeﬁnitions [7,8]. Clinical data are prospectively collected for
28 days and registered in a central database. No patients have
been treated with recombinant human activated protein C. A
search of the database conducted in September 2015 indicated
232 patients with ICU-acquired sepsis who were treated with
IgGAM. It was then decided by a panel of experts (AA, EA, CR,
EJGB, GV, KM, NK and VK) to design a protocol in which
patients treated with IgGAM and well-matched comparators
would be further analysed. Inclusion criteria were: (a) severe
sepsis or septic shock; (b) primary or secondary bacteraemia or
VAP by one MDR Gram-negative pathogen isolated either from
the blood or from tracheobronchial secretions or from bron-
choalveolar lavage; isolates from quantitative cultures of
tracheobronchial secretions or from bronchoalveolar lavage at
counts >105 CFU/mL or 104 CFU/mL, respectively, were
eligible; and (c) start of IgGAM <24 h from the development of
the ﬁrst signs of infection. An isolate resistant to antimicrobials
of at least three different chemical classes was considered MDR
[9]. Isolates susceptible to only one antimicrobial were
considered extensively drug-resistant (XDR) [9]. Exclusion
criteria were: (a) infection by the human immunodeﬁciency
virus; (b) neutropenia deﬁned as <1000 neutrophils/mm3; (c)
chronic intake of corticosteroids deﬁned as the intake of
>0.4 mg/kg of equivalent prednisone daily for >15 consecutive
days; (d) any primary immunodeﬁciency; (e) isolation of
coagulase-negative Staphylococcus spp. and of skin commensals;
(f) catheter-related infections; (g) more than one isolate from
tracheobronchial secretions or from bronchoalveolar lavage;
and (h) end of life (do not resuscitate) decision.
The following information was analysed per patient: de-
mographics, co-morbidities, Charlson’s co-morbidity index
(CCI) [10], type of infection, failing organs, Acute Physiology and
Chronic Health Evaluation (APACHE) II score, Sequential Organ
Failure Assessment (SOFA) score, daily dose and total duration
of IgGAM treatment, microbiology and antibiogram of the iso-
lated microorganism, type and dose of administered antimicro-
bial(s), appropriateness of the administered antimicrobial(s),
white blood cell count, daily blood cultures and 28-day outcome.
Appropriateness of the administered antimicrobial(s) was
deﬁned as the administration of at least one antimicrobial active
against the isolated pathogen according to the antibiogram.
Organ failures were deﬁned according to international deﬁni-
tions [7]. Breakthrough bacteraemia was considered as the
advent of a new episode of bloodstream infection developing in a
patient with sterile blood cultures for at least 72 h.
The comparators were selected among patients of the HSSG
database to be of the same number as the IgGAM group using a
stepwise matching process. Matching criteria were predeﬁned by
the same expert panel and required the same inclusion and
exclusion criteria as the IgGAM group. The following steps appliediology and Infectious Diseases, CMI, 22, 499–506
nses/by-nc-nd/4.0/).
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study sites and the same year; (b) severe sepsis/septic shock; (c)
appropriateness of empirical antimicrobial treatment; (d) source
of infection by MDR Gram-negative bacteria; and (e) CCI.
Study end points
The study end points and the statistical methods to be used
were predeﬁned. The primary end point was all-cause 28-day
mortality. The secondary end points were: (a) the impact of
IgGAM in the 28-day outcome of infections by XDR bacteria;
and (b) the impact of IgGAM on the time until breakthrough
bacteraemia. Post hoc analysis was also performed for the
impact of IgGAM on patient subgroups.
Statistical analysis
The matching procedure was performed using the case–control
matching command found in IBM SPSS Statistics version 22. This
command requires the Python Essentials. Comparisons of
baseline characteristics were performed with the independent
samples t-test for continuous variables and with the chi-square
test for frequency distributions. The primary outcome was
compared between the two groups with the Fisher exact test.
The OR were also reported with their 95% CI. The 28-day
survival distributions of the two groups were compared withFIG. 1. Case–control matching process. Abbreviations: CCI, Charlson’s C
preparation; MDR, multidrug-resistant.
© 2016 The Authors. Published by Elsevier Ltd on behalf
This is an open access articKaplan–Meier survival analysis using the log-rank test. The same
analysis was applied with regards to the secondary end points.
Univariate analyses for qualitative variables between survi-
vors and non-survivors were carried out by the Fischer exact
test. Then a stepwise logistic regression model was applied with
outcome on day 28 as the dependent variable and all the var-
iables found to have a signiﬁcant effect on the outcome at the
univariate analysis as the independent predictors. Finally, based
on the results of the stepwise logistic regression, the primary
outcome was once again regressed across the two groups
(comparators versus IgGAM) in the absence and presence of
the conditions found to have a signiﬁcant effect on 28-day
mortality. The aim was to ﬁnd in which conditions the admin-
istration of IgGAM was more beneﬁcial.
All the above analyses were performed with the IBM SPSS
Statistics version 22. The statistical signiﬁcance level was set to
0.05.ResultsGroups of comparisons and matching process
From the 222 patients treated with IgGAM, 100 met all the
inclusion criteria and none of the exclusion criteria (Fig. 1).o-morbidity Index; IgGAM, IgM-enriched polyclonal immunoglobulin
of European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, 499–506
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shown in Fig. 1, 100 comparators meeting all the same inclusion
criteria and none of the exclusion criteria were selected.
The mean daily dose of IgGAM was 30 g and it was admin-
istered as a 5- to 6-h continuous daily infusion for 5 days.
Baseline characteristics of each group are shown in Table 1.
Cases treated with IgGAM had a signiﬁcantly greater baseline
disease severity, as shown by the signiﬁcantly greater SOFA
score and the greater proportion of multiple organ dysfunction
syndrome. The frequency of acute coagulopathy was greater in
the IgGAM group at baseline, i.e. before the start of treatment
with the IgGAM preparation. Empirically prescribedTABLE 1. Comparative characteristics of cases treated with an IgM-
of matched comparators
C
Gender, male/female 6
Age (years), mean ± SD 5
Mechanical ventilation 1
Septic shock/severe sepsis 8
APACHE II score, mean ± SD 2
SOFA score, mean ± SD 8
SOFA subscore for PO2/FiO2 2
SOFA subscore for platelets 0
SOFA subscore for creatinine 1
SOFA subscore for bilirubin 0
SOFA subscore for vasopressors 1
SOFA subscore for Glasgow coma scale 2
White blood cells (/mm3), mean ± SD 1
PO2/FiO2 (mmHg), mean ± SD 2
Appropriateness of empirically administered antimicrobials on day 1, Yes/No 5
Source of sepsis
Primary bacteraemia 2
VAP 5
VAP and secondary bacteraemia 1
IAI and secondary bacteraemia 2
Isolated pathogens (n)
Acinetobacter baumannii 5
Klebsiella pneumoniae 2
Pseudomonas aeruginosa 2
Other 9
Polymicrobial infection (n) 2
Failing organs
Acute respiratory distress syndrome 5
Acute kidney injury 2
Cardiovascular shock 8
Metabolic acidosis 2
Acute coagulopathy 2
Presence of multiple-organ dysfunction 6
Coagulation abnormalities
Platelets <100 000/mm3 1
International normalized ratio >1.5 3
Reason for ICU admission
Multiple injuries 2
Acute respiratory failure 2
Community-acquired severe sepsis 1
Stroke 1
Head injury 1
Brain haemorrhage 9
Predisposing conditions
Type 2 diabetes mellitus 1
Chronic respiratory failure 2
Chronic heart failure 2
Chronic renal disease 1
Malignancy 1
Charlson’s co-morbidity index (mean ± SD) 2
Adjunctive therapies
Vasopressors 8
Low-dose hydrocortisone replacement 4
Tight glucose control 4
Continuous veno-venous haemoﬁltration 1
Abbreviations: APACHE, acute physiology and chronic health evaluation; IAI, intrabdominal
pneumonia.
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
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(see Supplementary material, Table S1) and the same applied for
the resistance rates of the isolated pathogens (see
Supplementary material, Fig. S1).
Primary end point: all-cause 28-day mortality
The all-cause 28-day mortality among the comparators was 58/
100 whereas in the IgGAM group it was 39/100 (p 0.011). For
death under IgGAM the OR was 0.46 (95% CI 0.26–0.81). The
statistically signiﬁcant differences pertain with regards to the
28-day survival curves in the IgGAM and the comparator group
(Fig. 2).enriched polyclonal immunoglobulin preparation (IgGAM) and
omparators (n [ 100) IgGAM (n [ 100) p
6/34 70/30 0.544
4.2 ± 18.4 51.9 ± 18.6 0.399
00 100 1.000
6/14 86/14 1.000
0.7 ± 6.6 19.6 ± 6.9 0.229
.9 ± 3.3 10.2 ± 3.3 0.013
.19 ± 1.25 2.14 ± 1.37 0.788
.53 ± 1.08 1.36 ± 1.46 <0.0001
.33 ± 1.40 0.62 ± 1.07 <0.0001
.68 ± 0.90 1.11 ± 1.03 0.003
.90 ± 1.35 2.09 ± 1.22 0.358
.17 ± 1.30 2.83 ± 1.51 0.001
4 509.3 ± 9495.6 13 254.4 ± 9834.9 0.360
18.1 ± 111.6 169.7 ± 133.5 0.012
1/49 51/49 1.000
0.730
4 18
6 63
8 17
2
0.287
9 55
5 30
5 17
10
1 13 0.187
7 73 0.026
6 15 0.079
6 86 1.000
6 23 0.743
5 52 <0.0001
4 84 0.002
8 42 <0.0001
1 24 0.265
2 25 0.739
1 13 0.187
7 21 0.471
5 9 0.199
5 18 0.704
14 0.376
8 18 1.000
1 13 0.187
1 16 0.467
0 3 0.082
5 12 0.680
.86 ± 2.68 2.67 ± 2.43 0.601
6 86 1.000
4 63 0.007
3 32 0.144
4 22 0.197
infection; SOFA, sequential organ failure assessment; VAP, ventilator-associated
iology and Infectious Diseases, CMI, 22, 499–506
nses/by-nc-nd/4.0/).
FIG. 2. Survival plots for the patients
treated with an IgM-enriched polyclonal
immunoglobulin preparation (IgGAM)
and the comparator group until day 28;
statistical comparison between the two
groups is shown.
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variate analysis was carried out between survivors and non-
survivors (Table 2). This analysis showed that treatment with
IgGAM, SOFA >10, CCI >2, the presence of acute kidney
injury, the presence of acute coagulopathy, the presence of
cardiovascular failure, chronic respiratory failure, chronic renalTABLE 2. Univariate analysis between survivors and non-survivors
Variablea Survivors, (n [ 103) No
IgGAM treatment 61 (59.2) 39
SOFA >10b 27 (26.2) 44
Charlson-co-morbidity index >2b 36 (35.0) 60
White blood cells (/mm3), mean ± SD) 12 825.1 ± 8473.4 15
ARDS 66 (64.0) 64
Acute kidney injury 13 (12.6) 28
Acute coagulopathy 30 (29.1) 47
Metabolic acidosis 18 (17.5) 31
Cardiovascular failure 82 (79.6) 90
Type 2 diabetes mellitus 18 (17.5) 18
Chronic heart failure 17 (16.5) 20
Chronic respiratory failure 9 (8.7) 25
Chronic renal disease 2 (1.9) 11
Solid tumour malignancy 11 (10.7) 16
Stroke 10 (9.7) 14
Brain injury 23 (22.3) 10
Multiple injuries 34 (33.0) 13
Brain haemorrhage 15 (14.6) 8 (
Low hydrocortisone replacement 50 (48.5) 57
Tight glucose control 31 (30.2) 44
Continuous veno-venous haemoﬁltration 12 (11.7) 24
Abbreviations: ARDS, acute respiratory distress syndrome; IgGAM, IgM-enriched polyclonal
aAll values given as n (%) unless otherwise stated.
bRefers to the respective median value.
© 2016 The Authors. Published by Elsevier Ltd on behalf
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control and continuous veno-venous haemoﬁltration were
related with unfavourable outcome. These factors entered into
a stepwise regression analysis model. SOFA >10 and CCI >2
were excluded from this model because they are correlated to
the other variables. This model (Table 3) showed thatn-survivors (n [ 97) p OR 95% CIs
(40.2) 0.008 0.46 0.26–0.82
(45.4) 0.005 2.34 1.29–4.23
(61.9) <0.0001 3.02 1.67–5.37
003.9 ± 10 714.3 0.116 1.26 0.94–1.69
(66.0) 0.778 1.09 0.61–1.95
(28.9) 0.004 2.81 1.36–5.82
(48.5) 0.005 2.29 1.28–4.09
(32.0) 0.017 2.22 1.14–4.31
(92.8) 0.010 3.29 1.33–8.15
(18.6) 0.842 1.08 0.52–2.22
(20.6) 0.454 1.31 0.64–2.69
(25.8) 0.001 3.68 1.56–8.25
(11.3) 0.007 6.46 1.39–29.95
(16.5) 0.229 1.65 0.73–3.77
(14.6) 0.291 1.59 0.67–3.77
(10.4) 0.024 0.40 0.18–0.90
(13.5) 0.001 0.32 0.16–0.65
8.3) 0.170 0.53 0.22–1.32
(58.8) 0.148 1.51 0.86–2.64
(45.4) 0.027 1.93 1.08–3.45
(24.7) 0.018 2.49 1.17–5.32
immunoglobulin preparation; SOFA, sequential organ failure assessment.
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TABLE 3. Results of the stepwise logistic regression model
Predictor p OR 95% CI
IgGAM treatment 0.002 0.34 0.17–0.67
Acute coagulopathy <0.0001 3.53 1.74–7.16
Cardiovascular failure 0.003 4.77 1.68–13.56
Chronic respiratory failure 0.003 3.90 1.61–9.47
Chronic renal disease 0.026 7.18 1.27–40.58
Abbreviations: IgGAM, IgM-enriched polyclonal immunoglobulin preparation.
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favourable outcome.
The same model showed that acute coagulopathy, cardio-
vascular failure, chronic respiratory failure and chronic renal
disease were independent predictors of unfavourable
outcome. Cross-tabulation indicated that treatment with
IgGAM was beneﬁcial in patients with cardiovascular failure
whereas in the case of acute coagulopathy and chronic respi-
ratory failure, IgGAM did not seem to provide the additional
beneﬁt that seemed to provide in the absence of these two
conditions (Table 4). Finally, in the case of chronic renal dis-
ease, the question of the beneﬁcial effect of IgGAM adminis-
tration remained unanswered because of the small number of
patients.
Secondary end points
Sixty-two patients of the comparator group and 65 patients of
the IgGAM group were infected by XDR Gram-negative bac-
teria; 39 patients (62.9%) and 25 patients (38.5%), respectively,
died until 28-day by all-causes (p 0.008). The OR for death by
XDR Gram-negative bacteria treated with IgGAM was 0.37
(95% CI 0.18–0.76).
Thirty comparators and 65 patients treated with IgGAM had
sterile blood cultures for more than 72 h during their follow up
and could be evaluated for the development of breakthrough
bacteraemia; 12 patients (40.0%) and 22 (33.8%) patients
respectively developed breakthrough bacteraemia (p 0.682).
The median time to breakthrough bacteraemia was 4 days forTABLE 4. Modulation of the effect of independent predictors of 28
immunoglobulin preparation (IgGAM)
Predictor Condition
Comparators
Deaths/exposed patie
Acute coagulopathy Absence 41/75 (54.7)
Presence 17/25 (68.0)
Cardiovascular failure Absence 4/14 (28.6)
Presence 54/86 (62.8)
Chronic respiratory failure Absence 42/79 (53.2)
Presence 16/21 (76.2)
Chronic renal disease Absence 49/90 (54.4)
Presence 9/10 (90.0)
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licethe comparators (range 3–6 days) and 10 days for the IgGAM-
treated cases (range 7–12 days) (Fig. 3).DiscussionThe presented analysis comprises a meaningful number of pa-
tients with severe infections by MDR Gram-negative bacteria
treated with one IgM-enriched immunoglobulin preparation.
Results indicate a considerable survival beneﬁt on all-cause 28-
day mortality and on delay until one breakthrough bloodstream
infection. Analysis indicated that most of the survival beneﬁt
was found among patients with cardiovascular failure and for
infections by XDR Gram-negative bacteria. This translates to
the need for an early start of IgGAM when surveillance cultures
suggest a probability for XDR pathogens where the risk for
inappropriate initial antimicrobial therapy is high.
The rationale of supplementation with IgM preparations for
the management of severe infections is to neutralize bacterial
endotoxins and exotoxins and to enhance phagocytosis of
evading pathogens. A recent study of the HSSG reported
circulating IgM in patients with sepsis, 113 of which were
classiﬁed as severe sepsis and 78 as septic shock. Considerable
reduction of IgM was found in septic shock. When circulating
IgM was measured on sequential days after start of vaso-
pressors in septic shock, it was found that the distribution of
IgM was lower in non-survivors than in survivors from septic
shock [11]. This corroborates very well the reported ﬁnding
in this analysis where most of the survival beneﬁt was shown
in cardiovascular failure; this is the stage of sepsis where
deﬁcient distribution of IgM in the host is occurring. Others
[12] have shown profound hypoglobulinaemia of not only IgM
but also of IgG and IgA immunoglobulins on the ﬁrst day of
septic shock. The studied IgGAM preparation contains IgG
immunoglobulins as well, so part of the beneﬁciary action may
be related to the supplementation of missing IgG along with
the missing IgM.-day mortality by treatment with the IgM-enriched polyclonal
IgGAM
p OR 95% CIsnts (%)
9/48 (18.8) <0.0001 0.19 0.08–0.45
30/52 (57.7) 0.385 0.64 0.24–1.75
3/14 (21.4) 0.613 0.68 0.12–3.83
36/86 (41.9) 0.004 0.43 0.23–0.79
30/87 (34.5) 0.015 0.46 0.29–0.87
9/13 (69.2) 0.655 0.7 0.15–3.31
37/97 (38.1) 0.025 0.52 0.29–0.92
2/3 (66.7) 0.326 0.22 0.09–5.28
iology and Infectious Diseases, CMI, 22, 499–506
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FIG. 3. Time to breakthrough bacter-
aemia for cases treated with an IgM-
enriched polyclonal immunoglobulin
preparation (IgGAM) and matched com-
parators; statistical comparison between
the two groups is shown.
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20 years on the efﬁcacy of immunoglobulin preparations for
patients with severe infections. Available trials are character-
ized by great heterogeneity regarding monoclonality or poly-
clonality and IgG or IgM content of the administered
preparations. Trials have been conducted in both neonates and
adults and in most of them the number of enrolled patients is
limited. The most recent meta-analysis tried to overcome these
sources of bias and reported separately on each situation. Part
of the meta-analysis was done with seven trials with a total of
528 adult participants with severe sepsis or septic shock treated
either with IgGAM or placebo or no intervention. The OR for
all-cause mortality was 0.66 with moderate risk of bias (95% CI
0.51–0.84) [13]. A former meta-analysis comprising ten ran-
domized trials conducted both in neonates and in adults has
shown that most of the survival beneﬁt from IgGAM treatment
is for patients with septic shock by Gram-negative bacteria [14].
Two main limitations of our study should be recognized: (a)
the retrospective nature; and (b) the lack of comparators
treated with IgG preparations or some other appropriate
comparator like albumin. Despite these limitations, some
strong points of the study should be underscored: (a) the more
severe status of cases treated with IgGAM than comparators as
reﬂected by the higher SOFA score and the prevalence of
multiple organ dysfunction syndrome; and (b) the lack of© 2016 The Authors. Published by Elsevier Ltd on behalf
This is an open access articheterogeneity because in all treated cases of our study, IgGAM
was started within the ﬁrst 24 h from signs of infection. This
provides homogeneity in the analysed cohort, which is missing
in previous published trials where no precise time limit be-
tween start of signs of infection and start of IgGAM treatment
applied [15]. The importance of time delay in the start of
IgGAM has also been shown in one retrospective analysis of
129 patients; survivors were started on IgGAM treatment
earlier than non-survivors (23 versus 63 h) [16].
Our results corroborate one analysis of 57 cases of septic
shock treated with IgGAM and another 57 propensity-matched
non-treated comparators. Treatment with IgGAM was associ-
ated with signiﬁcant survival beneﬁt. However, this study failed
to report on the impact of microbiology of treated cases and of
co-administered antimicrobial treatment [17].
The present study provides promising data supporting the
use of polyclonal IgM-enriched immunoglobulin preparations as
adjunctive of antimicrobial treatment for the management of
severe infections caused by MDR Gram-negative bacteria.
These pathogens progressively emerge in critically ill patients,
causing infections with reported mortality even exceeding 50%
[18,19]. A prospective randomized trial is warranted to prove
the role of polyclonal IgM-enriched preparations as an adjunc-
tive therapeutic strategy for severe infections by MDR Gram-
negative bacteria.of European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, 499–506
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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